Estrella Immunopharma, Inc. (ESLAW) — Operating Income
| Fiscal Year | Operating Income | Change YoY |
|---|---|---|
| 2025 | -$13.06M | -78.7% |
| 2024 | -$7.31M | +34.2% |
| 2023 | -$11.11M | -608.1% |
| 2022 | -$1.57M | -530.0% |
| 2021 | -$249.1K | — |
| Fiscal Year | Operating Income | Change YoY |
|---|---|---|
| 2025 | -$13.06M | -78.7% |
| 2024 | -$7.31M | +34.2% |
| 2023 | -$11.11M | -608.1% |
| 2022 | -$1.57M | -530.0% |
| 2021 | -$249.1K | — |